Jump to content

WAY-629

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by JCW-CleanerBot (talk | contribs) at 01:56, 14 November 2017 (top: task, replaced: Bioorganic and Medicinal Chemistry Letters → Bioorganic & Medicinal Chemistry Letters using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

WAY-629
Names
IUPAC name
1,2,3,4,8,9,10,11-Octahydro[1,4]diazepino[6,7,1-jk]carbazole
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C15H18N2/c1-2-7-14-12(5-1)13-6-3-4-11-10-16-8-9-17(14)15(11)13/h3-4,6,16H,1-2,5,7-10H2
    Key: OIGHTPDWPMLMGT-UHFFFAOYSA-N
  • InChI=1/C15H18N2/c1-2-7-14-12(5-1)13-6-3-4-11-10-16-8-9-17(14)15(11)13/h3-4,6,16H,1-2,5,7-10H2
    Key: OIGHTPDWPMLMGT-UHFFFAOYAM
  • C1CCC2=C(C1)C3=CC=CC4=C3N2CCNC4
Properties
C15H18N2
Molar mass 226.32 g mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

WAY-629 is a 5-HT2C agonist that reduces feeding behavior when administered to rats. It was used as a starting point for developing more potent and selective 5-HT2C agonists aimed at treating obesity.[1]

References

  1. ^ Sabb, AL (May 2004). "Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor". Bioorganic & Medicinal Chemistry Letters. 14 (10): 2603–7. doi:10.1016/j.bmcl.2004.02.100. PMID 15109661.